HB4172 103RD GENERAL ASSEMBLY

LRB103 34770 LNS 64620 b

103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB4172

Introduced , by Rep. Jehan Gordon-Booth

SYNOPSIS AS INTRODUCED:

New Act

Creates the Deveraux Hubbard II Blood Clot Prevention and Treatment Act. Requires the Department of Public Health to carry out projects to increase education, awareness, or diagnosis of deep venous thrombosis or pulmonary embolism and to reduce the incidence of morbidity and mortality caused by blood clots. Requires the Director of Public Health to establish the Advisory Committee for Deep Venous Thrombosis or Pulmonary Embolism Prevention. Sets forth the Advisory Committee's duties, membership, reporting requirements, and termination of the Advisory Committee. Requires the Department to conduct or support a study on model systems of deep venous thrombosis or pulmonary embolism surveillance and submit a report to the General Assembly detailing the results of the study.

A BILL FOR

AN ACT concerning health.

Be it enacted by the People of the State of Illinois, represented in the General Assembly:

Section 1. Short title. This Act may be cited as the Deveraux Hubbard II Blood Clot Prevention and Treatment Act.

Section 5. Prevention of morbidity and mortality as a result of deep venous thromboembolism.

(a) The Department of Public Health shall carry out projects to increase education, awareness, or diagnosis of deep venous thrombosis or pulmonary embolism and to reduce the incidence of morbidity and mortality caused by blood clots. The projects may be carried out by the Department directly or through awards of grants or contracts to public or nonprofit private entities. The Department may directly, or through awards or grants, provide technical assistance with respect to the planning, development, and operation of the projects.

(b) A project under this Section may include:

(1) the implementation of public information and education programs for:

(A) the prevention of death from deep venous thrombosis or pulmonary embolism;

(B) broadening the awards of the public concerning:

(i) the risk factors for and the symptoms of deep venous thrombosis or pulmonary embolism;

(ii) target populations with greater risk for deep venous thrombosis or pulmonary embolism, including women, seniors, cancer patients, hospitalized patients, pregnant and postpartum women, Black Americans, and those in rural areas; and

(iv) the public health consequences of deep venous thrombosis or pulmonary embolism; and

(C) increasing screening, detection, and diagnosis of deep venous thrombosis or pulmonary embolism; and

(2) surveillance of the prevalence and incidence of deep venous thrombosis or pulmonary embolism to improve patient outcomes.

(c) The Department may, in awarding grants or entering into contracts under this Section, give priority to entities seeking to carry out projects that target the populations referred to in item (ii) of subparagraph (B) of paragraph (1) of subsection (b).

(d) The Department shall ensure that projects carried out under this Section are coordinated, as appropriate, with other agencies that carry out activities regarding deep venous thrombosis or pulmonary embolism.

(e) The Department shall:

(1) collect and analyze the findings of research conducted with respect to deep venous thrombosis or pulmonary embolism; and

(2) taking into account such findings, publish on the Department's website the best practices for physicians and other health care providers who provide car to individuals with deep venous thrombosis or pulmonary embolism.

Section 10. Advisory Committee for Deep Venous Thrombosis or Pulmonary Embolism Prevention.

(a) Not later than 180 days after the effective date of this Act, the Director of Public Health shall establish an advisory committee to be known as the Advisory Committee for Deep Venous Thrombosis or Pulmonary Embolism Prevention.

(b) The Advisory Committee shall:

(1) identify the aggregate number of individuals in the State who experience deep venous thrombosis or pulmonary embolism annually;

(2) identify how data are collected regarding deep venous thrombosis or pulmonary embolism and the adverse outcomes associated with such conditions;

(3) identify how deep venous thrombosis or pulmonary embolism impacts the lives of individuals in the State;

(4) identify the standard of care for deep venous thrombosis or pulmonary embolism surveillance, detection, and treatment;

(5) identify emerging treatments, therapies, and research relating to deep venous thrombosis or pulmonary embolism;

(6) develop recommendations to help health care providers identify patients who may be at a higher risk of forming deep venous thrombosis or pulmonary embolism in health care facilities;

(7) develop recommendations to help improve patient awareness of deep venous thrombosis or pulmonary embolism;

(8) develop recommendations with respect to the standard of care for patients at risk of forming deep venous thrombosis or pulmonary embolism;

(9) develop recommendations relating to providing patients and their families with written notice of increased risks of forming deep venous thrombosis or pulmonary embolism; and

(10) identify the estimated level of State funding needed for deep venous thrombosis or pulmonary embolism services to met the needs of high-risk populations.

(c) The Advisory Committee shall be composed of members appointed by the Director as follows:

(1) at least one individual who has experienced blood clots;

(2) at least one family member of an individual who died from deep venous thrombosis or pulmonary embolism;

(3) at least one health services researcher;

(4) at least one health care provider;

(5) at least one representative of a health plan;

(6) at least one representative of a hospital or health system;

(7) at least one epidemiologist;

(8) at least one public health expert;

(9) at least one patient representative or representative of a patient group;

(10) at least one physician licensed to practice medicine in all its branches and who represents a statewide organization of physicians; and

(11) such individuals representing other interested parties or associations, as the Director determines appropriate.

(d) Not later than 18 months after the first meeting of the Advisory Committee, the Director shall submit to the General Assembly, and make publicly available, a report:

(1) summarizing the meetings and findings of the Advisory Committee; and

(2) describing the recommendations of the Advisory Committee for legislative and administrative action to improve deep venous thrombosis or pulmonary embolism prevention, treatment, and diagnosis, including the recommendations described in paragraphs (6) through (9) of subsection (b).

(e) The Advisory Committee shall terminate on the earlier of:

(1) the date on which the Director submits the report under subsection (d); or

(2) the date that is 18 months after the first meeting of the Advisory Committee.

Section 15. Deep venous thrombosis or pulmonary embolism surveillance study and report.

(a) The Department of Public Health shall conduct or support a study on model systems of deep venous thrombosis or pulmonary embolism surveillance, including the use of electronic medical record-based methods of detecting deep venous thrombosis and pulmonary embolism International Classification of Diseases codes or other population-based surveillance.

(b) Not later than one year after the effective date of this Act, the Department shall submit to the General Assembly and the Advisory Committee for Deep Venous Thrombosis or Pulmonary Embolism a report detailing the results of the study under subsection (a).